REM Sleep Behavior Disorder and α-synucleinopathy Tomoyuki Miyamoto 1 , Kyoko Numahata 1 , Hideaki Ishido 1 , Masayuki Miyamoto 2,3 1Department of Neurology, Dokkyo Medical University Saitama Medical Center 2Department of Clinical Medicine for Nursing, Dokkyo Medical University School of Nursing 3Center of Sleep Medicine, Dokkyo Medical University Hospital Keyword: レム睡眠行動異常症 , レヴィ小体病 , パーキンソン病 , レヴィ小体型認知症 , 多系統萎縮症 , REM sleep behavior disorder , Lewy body disease , Parkinson's disease , dementia with Lewy bodies , multiple system atrophy pp.107-117
Published Date 2020/2/1
DOI https://doi.org/10.11477/mf.1416201490
  • Abstract
  • Look Inside
  • Reference


REM sleep behavior disorder (RBD) can progress to Parkinson's disease, Lewy body dementia, or multiple system atrophy within 20 years of onset. Accurate diagnosis of RBD is therefore important for early intervention. The development of markers that can more sensitively evaluate the effects of high-risk groups or candidate therapies that develop α-synucleinopathy in the short term is the key to a successful clinical trial. Clinical protocols for early diagnosis of α-synucleinopathy are currently being developed. The next stage will be to conduct clinical trials for candidate therapies.

Copyright © 2020, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院